Selling a Dermatology Practice Business in Richmond, VA — 2026 Market Guide

Dermatology practices in Richmond, VA are selling at 6x-11x EBITDA in 2026, with multi-provider practices combining medical, Mohs, and cosmetic revenue commanding the high end of that range. The Richmond metro led Virginia in population growth from 2020 to 2023 and continues to attract healthcare investment. Educational & Health Services employs roughly 117,000 people across the metro, making it one of the region's largest employment sectors. Major health systems include VCU Health, Bon Secours Richmond, and HCA Virginia, creating a dense commercial payor base and strong referral infrastructure for specialty practices.

At a Glance — Richmond, VA

  • 6.0x-11.0x EBITDA: Typical Multiple Range
  • Epiphany, ADCS, USDP, Forefront + PE: Active Buyers
  • 6-12 Months: Typical Timeline
  • $1M-$8M EBITDA: Sweet Spot

What Makes Richmond's Dermatology Market Different?

Richmond's market has three structural advantages that buyers pay up for. First, demographics — Richmond led Virginia in population growth from 2020-2023, and labor force participation at 66.9% runs well above the 63.5% national average, meaning the commercially insured population is deep and growing. Second, health system density — VCU Health, Bon Secours Richmond, HCA Virginia, and Chippenham Hospital anchor clinical referral networks that feed specialty demand, while Capital One, Altria, Dominion Energy, Federal Reserve, and state government employers provide the commercial insurance backbone. Third, the metro's I-95 corridor position between Washington DC and Raleigh makes Richmond a natural expansion target for DC-area and Carolinas-based dermatology platforms.

Dermatologist compensation in Virginia averages approximately $464K annually, with top-quartile earners reaching $650K+, signaling strong demand relative to supply — which directly translates to attractive practice economics for buyers. Richmond also has established dermatology groups such as Dermatology Associates of Virginia, Richmond Dermatology, Elevate Dermatology & Plastic Surgery, and Absolute Dermatology & Skin Cancer Center, creating a mature market with established cosmetic and Mohs infrastructure. Owners considering a sale should review the broader dermatology valuation framework alongside the Richmond market hub.

Who's Buying Dermatology Practices in Richmond?

National strategic acquirers active in Richmond include Epiphany Dermatology (the most active dermatology platform consolidator with 39 deals over five years), Advanced Dermatology & Cosmetic Surgery (ADCS), US Dermatology Partners, Forefront Dermatology, Schweiger Dermatology Group, and Pinnacle Dermatology. PE-backed platforms from LGP Capital, Harvest Partners, Morgan Stanley Capital Partners, New MainStream Capital, and Audax Group have all closed Mid-Atlantic add-ons in the past 24 months. Regional platforms headquartered in DC, Northern Virginia, and the Carolinas are increasingly targeting Richmond as a priority expansion market.

VCU Health and Bon Secours periodically acquire dermatology assets, though those transactions typically target practices with significant academic or referral-anchored positioning. For most independent Richmond dermatology sellers, the realistic buyer pool is 6-10 serious PE-backed and strategic platform bidders, and a competitive process commonly produces 4-7 LOIs in practices generating $1.5M+ EBITDA.

What Do Dermatology Practices Sell For in Richmond?

Richmond dermatology multiples follow the national ranges with a slight metro-level premium for practices serving the commercial payor base. A single-provider practice with $400K-$600K EBITDA typically sells at 3.5x-5x. A small group with $800K-$1.5M EBITDA and a Mohs surgeon reaches 6x-8x. Multi-provider practices with $1.5M-$4M EBITDA, diversified medical/surgical/cosmetic mix, and non-owner provider leverage command 8x-11x. Regional platforms with multiple Richmond-area locations and $4M+ EBITDA have reached 11x-13x in the last 18 months.

Mohs-heavy practices earn a premium because of structural demand and high margins. Cosmetic-heavy practices serving Richmond's professional and executive base — Capital One, Altria, law firms, healthcare administrators — get strong credit for cash-pay cosmetic revenue, though buyers model cosmetic at a slightly lower multiple than medical derm revenue. The sweet spot in Richmond is $1M-$3M EBITDA with at least one recruited associate, at least one Mohs surgeon, and 20-30% cosmetic revenue.

What Do Richmond Dermatology Owners Need to Know?

Three things specific to the Richmond market. First, Anthem BCBS of Virginia is the dominant commercial payor, and your contracted rates and credentialing status with Anthem drive a substantial portion of valuation — buyers will want rate schedules for every CPT code material to your practice and credentialing status for every active provider. Second, Virginia's certificate-of-public-need (COPN) rules don't typically apply to office-based dermatology, but buyers still diligence state regulatory status, especially around any laser or ambulatory surgery center capacity in the practice. Third, the Richmond market has a deep clinical labor pool (VCU School of Medicine, residency training programs, experienced mid-levels), which means buyer diligence focuses heavily on clinician retention plans and employment agreements — practices with post-transaction provider commitments in place close faster and at higher multiples.

"A Richmond dermatology practice I sold in Q4 2025 — two physicians including a Mohs surgeon, one recruited associate, $1.6M EBITDA, 60% medical / 20% Mohs / 20% cosmetic split, strong Anthem contract — ran a competitive process with six LOIs and closed at 9.4x EBITDA with an ADCS-related platform. The buyer paid the premium specifically for the Mohs capacity and the recruited associate. Richmond is a market where buyers pay up for clinical depth and commercial payor mix — the demographic tailwind and employer base give them confidence in durable patient volume."

— John M. Salony, Business Broker

Find Out What Your Business Is Worth in Richmond

Start with the free valuation calculator to see what your Richmond practice is worth in today's market. From there we can set up a confidential consultation to walk through Mohs, cosmetic, and Anthem contract levers specific to your practice.

Schedule a Confidential Consultation

Frequently Asked Questions

What Makes Richmond's Dermatology Market Different?
Richmond's market has three structural advantages that buyers pay up for. First, demographics — Richmond led Virginia in population growth from 2020-2023, and labor force participation at 66.9% runs well above the 63.5% national average, meaning the commercially insured population is deep and growing. Second, health system density — VCU Health, Bon Secours Richmond, HCA Virginia, and Chippenham Hospital anchor clinical referral networks, while Capital One, Altria, Dominion Energy, Federal Reserve, and state government employers provide the commercial insurance backbone. Third, Richmond's I-95 corridor position between DC and Raleigh makes it a natural expansion target for DC-area and Carolinas-based dermatology platforms. Dermatologist compensation in Virginia averages $464K, signaling strong demand relative to supply — which translates to attractive practice economics for buyers.
Who's Buying Dermatology Practices in Richmond?
National strategic acquirers active in Richmond include Epiphany Dermatology (the most active dermatology platform consolidator with 39 deals over five years), Advanced Dermatology & Cosmetic Surgery (ADCS), US Dermatology Partners, Forefront Dermatology, Schweiger Dermatology Group, and Pinnacle Dermatology. PE-backed platforms from LGP Capital, Harvest Partners, Morgan Stanley Capital Partners, New MainStream Capital, and Audax Group have all closed Mid-Atlantic add-ons in the past 24 months. Regional platforms headquartered in DC, Northern Virginia, and the Carolinas are increasingly targeting Richmond. VCU Health and Bon Secours periodically acquire dermatology assets, though those target practices with significant academic or referral-anchored positioning. For most independent Richmond sellers, the realistic buyer pool is 6-10 serious PE-backed and strategic platform bidders, and competitive processes commonly produce 4-7 LOIs in practices generating $1.5M+ EBITDA.
What Do Dermatology Practices Sell For in Richmond?
Richmond dermatology multiples follow national ranges with a slight metro-level premium for practices serving the commercial payor base. A single-provider practice with $400K-$600K EBITDA typically sells at 3.5x-5x. A small group with $800K-$1.5M EBITDA and a Mohs surgeon reaches 6x-8x. Multi-provider practices with $1.5M-$4M EBITDA, diversified medical/surgical/cosmetic mix, and non-owner provider leverage command 8x-11x. Regional platforms with multiple Richmond-area locations and $4M+ EBITDA have reached 11x-13x in the last 18 months. Mohs-heavy practices earn a premium because of structural demand and high margins. Cosmetic-heavy practices serving Richmond's professional and executive base get strong credit for cash-pay cosmetic revenue, though buyers model cosmetic at a slightly lower multiple than medical derm. The sweet spot is $1M-$3M EBITDA with at least one recruited associate, at least one Mohs surgeon, and 20-30% cosmetic revenue.
What Do Richmond Dermatology Owners Need to Know?
Three things specific to the Richmond market. First, Anthem BCBS of Virginia is the dominant commercial payor, and your contracted rates and credentialing status with Anthem drive a substantial portion of valuation — buyers will want rate schedules for every material CPT code and credentialing status for every active provider. Second, Virginia's certificate-of-public-need (COPN) rules don't typically apply to office-based dermatology, but buyers still diligence state regulatory status, especially around any laser or ambulatory surgery center capacity. Third, the Richmond market has a deep clinical labor pool (VCU School of Medicine, residency training programs, experienced mid-levels), which means buyer diligence focuses heavily on clinician retention plans and employment agreements — practices with post-transaction provider commitments in place close faster and at higher multiples.